Literature DB >> 12019792

BiZyme: a novel fusion protein-mediating selection of vaccinia virus recombinants by fluorescence and antibiotic resistance.

Scott G Hansen1, Torrey A Cope, Dennis E Hruby.   

Abstract

Recombinant vaccinia virus is a useful and powerful tool for the expression and study of foreign genes. Methods that are currently available for the selection of vaccinia virus recombinants include the restoration of viral plaque-forming phenotype, the replication of viral DNA in the presence of BUdR or mycophenolic acid, and the maturation and propagation of virus under antibiotic selection. Though effective, each of these methods requires several weeks of concerted effort to isolate, purify, and amplify a potential recombinant virus. Here we report the development of a bifunctional enzyme (BiZyme) to simplify and expedite the isolation and purification of vaccinia virus recombinants. This novel selection marker is composed of an in-frame fusion between the genes encoding gfp and the neomycin phosphotransferase enzyme (neo). Remarkably, expression of the chimeric gfp-neo cassette in the presence of G418 confers both viability and fluorescence to transfected or recombinant virus-infected cells, indicating that both activities are retained within the fusion protein. Therfore, BiZyme was incorporated into a recombination plasmid (pGNR) to enable the concomitant insertion of a foreign gene of interest. Here we demonstrate that this selection/amplification process requires a minimum of 11 days to produce the desired vaccinia virus recombinants. Furthermore, recombinants produced in this fashion have been shown to express both biologically active enzymes and antigenically authenticforeign antigens. In addition to its use in the vaccinia virus vector system, the BiZyme bifunctional selection scheme should be applicable to other eukaryotic and prokaryotic expression systems, simply by coupling it to the appropriate host-specific transcription regulatory signals.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12019792     DOI: 10.2144/02325dd08

Source DB:  PubMed          Journal:  Biotechniques        ISSN: 0736-6205            Impact factor:   1.993


  5 in total

1.  Vaccinia reporter viruses for quantifying viral function at all stages of gene expression.

Authors:  Daniel K Rozelle; Claire Marie Filone; Ken Dower; John H Connor
Journal:  J Vis Exp       Date:  2014-05-15       Impact factor: 1.355

2.  Development of Vaccinia reporter viruses for rapid, high content analysis of viral function at all stages of gene expression.

Authors:  Ken Dower; Kathleen H Rubins; Lisa E Hensley; John H Connor
Journal:  Antiviral Res       Date:  2011-05-05       Impact factor: 5.970

3.  Expanding the repertoire of Modified Vaccinia Ankara-based vaccine vectors via genetic complementation strategies.

Authors:  David A Garber; Leigh A O'Mara; Jun Zhao; Sailaja Gangadhara; InChul An; Mark B Feinberg
Journal:  PLoS One       Date:  2009-05-06       Impact factor: 3.240

4.  Intranasal immunization with a vaccinia virus vaccine vector expressing pre-fusion stabilized SARS-CoV-2 spike fully protected mice against lethal challenge with the heavily mutated mouse-adapted SARS2-N501Y MA30 strain of SARS-CoV-2.

Authors:  Karen V Kibler; Mateusz Szczerba; Douglas Lake; Alexa J Roeder; Masmudur Rahman; Brenda G Hogue; Lok-Yin Roy Wong; Stanley Perlman; Yize Li; Bertram L Jacobs
Journal:  bioRxiv       Date:  2021-12-08

5.  Intranasal Immunization with a Vaccinia Virus Vaccine Vector Expressing Pre-Fusion Stabilized SARS-CoV-2 Spike Fully Protected Mice against Lethal Challenge with the Heavily Mutated Mouse-Adapted SARS2-N501YMA30 Strain of SARS-CoV-2.

Authors:  Karen V Kibler; Mateusz Szczerba; Douglas Lake; Alexa J Roeder; Masmudur Rahman; Brenda G Hogue; Lok-Yin Roy Wong; Stanley Perlman; Yize Li; Bertram L Jacobs
Journal:  Vaccines (Basel)       Date:  2022-07-23
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.